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Abstract 
A human ,U opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat p opiate receptor cDNA. 
The human p opiate receptor (NORl) shares 95% amino acid identity with the rat sequence. The expressed ,uORI recognizes tested opiate drugs 
and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat ,U opiate receptor. Effects 
on cyclic AMP are similar to those noted for the rat ,U opiate receptor. An 18 kb genomic lone hybridizing with the bOR1 cDNA contains 63 and 
489 bp exonic sequences flanked by splice donor/acceptor sequences. Analysis of hybridization to DNA prepared from human rodent hybrid cell 
lines and chromosomal in situ hybridization studies indicate localization to 6q24-25. An MspI polymorphism, producing a3.7 kb band, may prove 
useful in assessing this gene’s involvement in neuropsychiatric disorders involving opiatergic systems. 
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1. Introduction 
Opiate receptors [l-5], sites recognizing exogenous 
opiate drugs and endogenous opiate peptides, include the 
morphine-preferring p opiate receptor first defined by 
Martin and colleagues [2]. ,u receptor distributions and 
pharmacologic properties place them among the recep- 
tors most identified with the analgesic and addicting 
properties of opiate drugs [3-71. These receptors are 
G-linked members of the seven transmembrane domain 
neuropeptide receptor subfamily [S-14]. 
Recent studies have identified the cDNAs encoding 
rodent ,u [15-171, 6 [17-191 and FC opiate receptors 
[20-221, thus defining at least one member of each of the 
other major opiate receptor subclasses postulated by 
Martin, Kosterlitz, Hughes, and associates [l-5]. The ,u 
opiate receptor has the structure of a G-protein coupled 
receptor. G-protein receptor coupling was confirmed for 
rpOR1 [15-171; morphine effects adenyl cyclase in ex- 
pressing cells [5,23]. 
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Because of interest in ,u receptors as targets for devel- 
opment of selective analgesic and anti-addictive thera- 
pies [24-281, and because of interest in identifying ,u 
receptor gene markers that could detect individuals pos- 
sessing allelic variants of this gene that could confer 
differential susceptibility to abused drugs, we have used 
the rat ,u receptor cDNA identified in this laboratory [ 151 
to identify its human homolog. In the present study, we 
describe the sequence of the human p opiate receptor, 
identify the sodium- and GTP analog-sensitive high-af- 
finity binding that its’ expression confers on COS cells, 
document he changes in adenyl cyclase that opiate drugs 
can induce in expressing COS cells, assign it to a human 
chromosomal region, identify a MORl genomic clone 
and describe a polymorphic genetic marker at the 
WORl locus. These data document he biochemical and 
genetic nature of the principal human receptor for anal- 
gesic and addicting opiate ligands. 
2. Materials and methods 
Candidate human ,U opiate receptor cDNAs were obtained using 
several cDNA libraries screened with fragments of the rat opiate recep- 
tor rpOR1 radiolabeled by random priming to specific activities of lo9 
dpm/pg. p@OR 1 was a 2.1 kb cDNA obtained from a human cerebral 
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cortical cDNA library prepared by random and oligo-dT priming in 
I-Zap II (Stratagene). Filters were hybridized at 30°C in 29% formalde- 
hyde, 6 x SSPE, washed at 42°C in 0.4 x SSPE/O.l% SDS, and exposed 
overnight o X-ray film. Plasmids were autoexcised from lambda-Zap 
II phage DNA grown from positive plaques as described and analyzed 
by restriction mapping and cDNA sequencing. ph,uORl was subjected 
to complete sequencing using automated and manual methods as de- 
scribed [29], with sequence analyses using GCG software [30], and the 
insert was subcloned into the expression plasmid pcDNA1 to yield 
pcDNAlhpOR1, pHG4 was an 18 kb hpOR1 genomic clone isolated 
from a human genomic library prepared in lambda-Zap II phage (Strat- 
agene) using hybridization with the p@ORl cDNA and analysis by 
sequencing as described [30]. 
COS cells were transfected by electroporation with 20 &lo’ cells of 
plasmid pcDNAlhpOR1, grown for two to three days and tested for 
opiate receptor expression by radioligand binding as described [15], 
except hat whole cell suspensions were used. Adenyl cyclase activities 
were assessed by radioimmunoassay sdescribed [15]. Cells transfected 
with the pcDNA1 vector alone served as negative controls. 
A 1.2 kb 3’ fragment of h$ORl contained 526 bp of coding sequence 
beginning in the protein’s predicted second extracellular loop and dis- 
played nucleotide sequence 87% identical to the rat rpOR1 nucleotide 
sequence. This 1.2 kb fragment, and the genomic clone HG4, were 
radiolabeled by random priming, and used as hybridization probes in 
southern analyses of the somatic cell hybrid panels #l and #2 (BIOS 
Labs, New Haven, CT 06511). These panels contain different comple- 
ments of Hind111 digests of human chromosomes in 26 independent cell 
lines in 36 panels. The panels were incubated separately with each 
radiolabelled hybridization probe in 29% formamide/ x SSPE at 30°C 
overnight, washed with 0.1 x SSPE/O. 1% SDS for 30 min at 37°C then 
twice for 30 min at 60°C. Radioactive patterns were detected by 
phosphorimaging following overnight exposure. Probes were then re- 
moved from panels by incubation in water at 90°C for 20 min, with 
removal assessed by overnight autoradiographic phosphorimager xpo- 
sure. 
Higher resolution mapping of the hpOR1 gene was accomplished 
with chromosomal in situ hybridization. A genomic clone, pHG4, was 
nick-translated with biotin-14 dATP (BRL, Gaithersburg, MD), with 
81% incorporation as determined by tritium tracer incorporation. 
Slides with chromosome spreads were made from normal male lympho- 
cytes cultured with BrdU [31]. Fluorescence in situ hybridization was 
performed as described [32] with modifications. 12.5 ng@l biotinylated 
probe in 2 x SSCP, 50% formamide, 10% dextran sulfate, 0.5 flg/pl 
Cot-l DNA and 0.5 @PI salmon sperm DNA were denatured at 70°C 
for 5 min, preannealed at 37°C for 30 min, placed on slides and hybrid- 
ized at 37°C overnight. Slides were washed in 50% formamide/2xSSC 
at 43°C for 20 min, then twice for 5 min in 2 x SSC at 37°C. Biotinyl- 
ated probe was detected with FITC-avidin and biotinylated anti-avidin 
[33]; (Oncor, Inc. Gaithersburg, MD), following manufacturer’s in- 
structions. 
DNA isolated from the leukocytes of 49 unrelated individuals sub- 
jected to experimental protocols at the Addiction Research Center, 
NIDA [34,35] was digested with BarnHI, EcoRI, HueIII, HindHI, 
Hid, MspI, PstI, RsaI, and TuqI and subjected to Southern analyses 
using the 1.2 kb 3’ radiolabeled hybridization probe. Only MspI diges- 
tion produced polymorphisms; no reproducible polymorphisms were 
present in lanes digested with other enzymes. 
3. Results 
Although several partial length cDNAs were obtained 
from other libraries, the 2.1 kb ph,~ORl appeared to 
contain the entire pOR1 open reading frame as well as 
3’ and 5’ untranslated sequences. The human cDNA dis- 
played an overall nucleotide identity of 79% with the rat 
cDNA; 87% nucleotide identity was noted in coding re- 
gions. This cDNA displayed an open reading frame with 
95% indentity to amino acids encoded by the rat p opiate 
receptor cDNA [15-171, 59% amino acid and 50% nucle- 
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Fig. 1 Predicted amino acid sequence of the human brain p opiate 
receptor (hMOR1). The sequence from the human cDNA clone 
hMOR1 is compared to the rat homologs of the p (rMOR1)[15-17],6 
(rDOR1)[17], and IC (rKOR1)[21-221 opiate receptor amino acid se- 
quences by using the program PILEUP. Boldface type and shading, 
transmembrane domain candidates; *, consensus sites for N-linked 
glycosylation; italics, amino acid residues different between rat and 
human p opiate receptor; @, indicates intron/exon boundary. The nu- 
cleotide sequence has been submitted to GenBank (#L25119) 
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otide identity with the rat IC receptor [21-221 and 62% 
amino acid and 59% nucleotide identity with the rat 6 
receptor [17] (Fig. 1). Amino acid identities with the rat 
somatostatin receptor [36], 40%, and j$ adrenergic recep- 
tor [37], 27%, were higher in transmembrane domains. 
This sequence manifests five N-terminal sites for poten- 
tial N-linked glycosylation, seven hydrophobic potential 
transmembrane domains, and sites for possible phospho- 
rylation characteristic of members of the G-protein 
linked receptor family (Fig. 1). An 18 kb human genomic 
subclone, pHG4, displayed sequence beginning in the 
middle of transmembrane domain 4 at its 5’ end, an 
intron between sequences encoding its’ second extracel- 
lular loop, another exon containing sequences encoding 
transmembrane regions 5-7 and the first 47 amino acids 
of the C-terminal domain, and a second intron (Fig. 1). 
The genomic clone failed to hybridize with an oligonucle- 
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otide complementary to a sequence located ca. 400 bp 
into the 3’ untranslated region of the cDNA (data not 
shown). Partial sequence analysis of this genomic clone 
thus identified 552 bp of sequence identical to those of 
the WORI cDNA. 
Expression of the WORl in COS cells revealed high 
affinity recognition of the p opiate specific ligand 
[3H]DAMG0 (D-ala2, N-methyl-phe4, glyo15) enkeph- 
alin with Kd 1.2 f 0.13 nM (Fig. 2). This binding was 
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Fig. 2. (A) Saturation analysis of [-‘H]DAMGO binding to COS cells 
transfected with pcDNA1 .h,uORl. Results of a representative experi- 
ments (4 replicas) are shown. The non-specific binding is fess than 15% 
of total radioactivity bound. The inset shows scatchard plots of the 
data. No significant [‘HIDAMGO binding could be detected in COS 
cells transfected with pcDNA1. (B) Functional coupling of hMOR1 to 
adenylate cyclase. COS-7 cells expressing the hMOR1 were initially 
treated with 1 mM IBMX for 15 min prior to being stimulated with 10 
,uM forskolin to elevate adenylate cyclase activity above basal levels. 
A fl-selective drug, peptide or naloxone were included in the medium 
at the concentrations indicated. Cellular CAMP levels were determined 
as described in the Section 2. Data are the mean + standard error from 
three experiments. 
displaced by a number of compounds recognizing p re- 
ceptors with high affinity. Morphine (4.1 + 1.4 nM), 
CTOP (o-phe-cys-tyr-o-trp-orn-thr-pen-thr-NH2; Penin- 
sula Labs; 16 f 6 nM), levorphanol and DADLE (D- 
ala2, o-leu5 enkephalin; 16 f 1.3 nM) displayed nano- 
molar affinities. U-50,488, DPDPE (o-pen2, o-pen5 
enkephalin), dextrorphan and dynorphin A 1-17 (284 *
110 nM) each displayed low affinities of less than 100 
nM. Each compound’s binding could be blocked by 1 
PM (-)naloxone. The addition of 50 ,uM Gpp(NH)p 
reduced the affinity of DAMGO more than three-fold. 
Addition of concentrations of sodium chloride as low as 
5 mM reduced binding affinity by two-fold. As noted for 
the rat ,u receptor, the human receptor can couple to 
adenylate cyclase. Addition of morphine or DAMGO to 
forskolin-stimulated COS cells expressing the human 
pOR1 transiently resulted in greater than 30% decreases 
in adenyl cyclase activity that were naloxone-reversible 
(Fig. 2B). 
Southern analyses revealed that both the human 
cDNA and genomic hybridization probes hybridized to 
total genomic DNA extracted from human but not from 
hamster. Southern analyses of DNA from 36 panels de- 
rived from 26 independent hamster/human somatic cell 
hybrid lines revealed that both the human cDNA and 
genomic hybridization probes hybridized to DNA from 
each of the six panels derived from four independent cell 
lines that contained human chromosome six. In studies 
using the cDNA hybridization probe, none of the 30 
panels derived from 22 independent cell lines containing 
material from human chromosomes other than six pro- 
duced a positive hybridization signal. No other human 
chromosome was uniformly present in cell lines produc- 
ing positive hybridization signals. Hybridization pat- 
terns with the genomic clone HG4, however, also re- 
vealed signals in four panels containing chromosome 3 
and two panels containing chromosome 5 (data not 
shown). 
Analysis of 42 metaphase cells by fluorescent in situ 
hybridization demonstrated 20 cells (48%) that had at 
least one pair of hybridization signals that involved both 
chromatids of a single chromosome. Thirty-two paired 
signals were seen; 23 (72%) were located near the termi- 
nal end of the long arm of a large C-group (chr. 6,7 or 
X) chromosome. To determine the specific chromosome 
and band, cells were G-banded by fluorescence plus 
Giemsa [31] techniques, and photographs of banding 
patterns aligned with photographs of the fluorescence in 
situ hybridization signals to determine sub-band loca- 
tion. Eighteen signals of 27 analyzable signals (67%) 
were on chromosome 6, bands q24-25 (Fig. 3A). Of the 
remaining 9 signals, seven were located on chromosome 
3, band q26, while two were on other chromosomes. 
Digestion with AluI, BumHI, EcoRI, HaelI, HindIII, 
HinjI, MspI, PstI, RsaI, and Tug1 produced constant 
bands detectable with the 1.2 kb WORl cDNA. How- 
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ever, MspI digestion produced hybridizing fragments of 
15.0, 7.5, 6.4, and a 3.7 kb that showed variability from 
individual to individual, creating a distinct polymorphic 
pattern (Fig. 3B). The 3.7 kb band was present in DNA 
from 31 of 49 (63%) of the Caucasian individuals studied. 
An apparently rare variant generated by the absence of 
the 15.0 kb band (Fig. 3B) was detected in only 2 (4.1%) 
of our 49 subjects. No band allelic with the 3.7 kb band 
could be identified in MspI digests. Conceivably, the 
other allele could comigrate with one of the constant 
bands in A4spI digests, or be unrecognized by the 1.2 kb 
3’ hybridization probe used here. 
4. Discussion 
These results document he nature and function of the 
human p opiate receptor. The high conservation of the 
receptor with the rat sequence, more than 95%, may 
reflect its important biological roles. The conservation 
Fig. 3. (A) Ideogram of human chromosome 6, displaying localization 
of hybridization with human pOR1 genomic sequences to 6q24-25. 
Each dot represents apaired hybridization signal noted on a G-banded 
metaphase chromosome. Signals clearly assigned to a single band are 
depicted to the right, those assigned to less precise regions indicated by 
brackets are depicted on the left side. (B) MspI RFLP patterns of DNAs 
extracted from leukocytes of 8 unrelated individuals probed with radi- 
olabeled 1.2 kb 3’ fragment of h,~0Rl (Lanes l-2, 3-9). Lane 3, no 
DNA. Fragment size estimates based on the mobilities of il phagel 
Hind111 DNA size markers were: 15.0 kb (upper band present in all 
DNAs except individual in lane 2); 7.5 and 6.4 kb (second and third 
bands present in all DNAs); 3.7 kb (present in individuals represented 
in lanes 2,4,7-9). 
also extends to function. Each of the measures of opioid 
peptide and drug affinities and second messenger activi- 
ties noted for the human receptor nicely parallels that 
noted for the rat. 
The previously best-studied model of the human ,u 
receptor may be the receptor expressed on the human 
neuroblastoma SH-SY 5Y cells [38]. In this cell line, the 
expressed receptor displays affinities for morphine, 
DAMGO and CTOP that are quite similar to values 
noted for our expressed cloned UORl [39-40]. This 
pharmacologic parallel is also manifest as the ability of 
a 500-base pair f agment of pbOR1 to protect RNA 
prepared from the human SH-SY 5Y cells in preliminary 
RNase protection experiments (A. Moriwaki, Y. Imai, 
and GRU, unpublished observations). Each of these re- 
sults is consistent with the notion that SH-SYSY cells 
may express the same pOR1 cDNA expressed by the 
plasmid whose cloning is reported here. SH-SYSY cells 
also display robust ,u receptor coupling to adenylyl 
cyclase [38,41] (P.S.J., data not shown). The current de- 
scription of p opiate receptor binding from the expressed 
human cDNA fits well with previous work describing the 
properties of the expressed rat ,u opiate receptor [15-171. 
Each of the studies of cloned p receptors to date has 
identified a receptor with high affinity for DADLE and 
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morphine, features imputed to a ‘,u,’ subtype of 1( opiate 
receptor defined by Pasternak and co-workers [3,42]. 
Both somatic cell hybrid panels probed with each of 
two @OR1 probes and chromosomal in situ hybridiza- 
tion studies using the longer genomic hybridization 
probe produce concordant hybridzation signals associ- 
ated with chromosome 6. Recognition of sequences on 
chromosome 3 and, in somatic cell hybrid studies, 5 by 
the HG4 genomic probe, but not by the cDNA, could be 
accounted for by hybridization to apparent repetitive 
sequences identified in the HG4 clone, but not in the 
cDNA (J.B.W. and X.-D. Yang, in preparation). 
Opiate receptor-mediated effects on several different 
second messenger systems, including adenylyl cyclase, 
have been suggested by neuropharmacologic studies [8- 
141. The human ,uORl receptor appears to be able to 
couple well to adenylyl cyclase, as noted for the rat recep- 
tor. The exact G-protein mechanisms, direct or indirect, 
whereby these effects are manifest remain to be eluci- 
dated. Interestingly, the rat p opiate receptor peptide 
purified by Eppler and colleagues co-purifies with a Gia3 
immunoreactive G-protein species [43]. 
Classical genetic studies, including family, twin and 
adoption approaches, suggest that individual differences 
in vulnerability to substance abuse are likely to be, at 
least in part, genetically determined [44-46]. ,u opiate 
receptor systems are plausible candidate genes that 
might display allelic variants contributing to these indi- 
vidual differences. Conceivably, such allelic variation 
could also contribute to individual differences in potency 
and power of opiate mediated analgesia, or to develop- 
ment of tolerance during chronic treatments. Informa- 
tion on the chromosomal assignment and polymorphic 
human genetic markers noted in this report could con- 
tribute to our abilities to assess possible human clini- 
cally-significant allelic variants in this most-analgesia- 
and-addiction-associated opiate receptor subtype. 
Acknowledgments: We thank Ms. Carol Sneeringer for assistance of the 
manuscript, David Vandenbergh for help with arranging the chromoso- 
ma1 in situ hybridization, David Surratt, Wen Fei Wang, and Jun Min 
Wu, Donna Walther and Xiaodong Yang for technical assistance, and 
support from the intramural program of the National Institute of Drug 
Abuse. 
References 
[I] Lord, J.A.H., Waterfield, A.A., Hughes, J. and Kosterlitz, H.W. 
(1977) Nature 267, 495499. 
[2] Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E. and 
Gilbert P.E. (1976) J. Pharmacol. Exp. Ther. 197, 517-532. 
[3] Wolozin, B.L. and Pasternak, G.W. (1981) Proc. Natl. Acad. Sci. 
USA 78, 61816185. 
[4] Su, T.-P, (1985) J. Pharmacol. Exp. Ther. 232, 144-148. 
[5] Stefano, G.B., Melchiorri, P., Negri, L., Hughes, T.K. and Schar- 
rer. B. (1992) Proc. Natl. Acad. Sci. USA 89, 93169320. 
[6] Clark, J.A., Liu, L., Price, M., Hersh, B., Edelson, M. and Paster- 
nak, G.W. (1989) J. Pharmacol. Exp. Ther. 251,461468. 
[7] Rothman, R.B., Bykov, V., DeCosta, B.R., Jacobson, A.E., Rice, 
K.C. and Brady, L.S. (1990) Peptides 11, 311-331. 
[8] Koski, G. and Klee, W.A. (1981) Proc. Natl. Acad. Sci. USA 78, 
41854189. 
[9] Koski, G., Streaty, R.A. and Klee, W.A. (1982) J. Biol. Chem. 257, 
14035-14040. 
[lo] Blume, A.J. (1978) Proc. Natl. Acad. Sci. USA 75, 1713-1717. 
[l l] Frances, B., Moisand, C. and Meunier, J.-C. (1985) Eur. J. Phar- 
macol. 117, 223-232. 
[12] Demoliou-Mason, C.D. and Barnard, E.A. (1986) J. Neurochem. 
46, 1118-l 128. 
[13] Makman, M.H., Dvorkin, B. and Crain, S.M. (1988) Brain Res. 
400, 185-190. 
[14] Miyake, M., MacDonald, J.C. and North, R.A. (1989) Proc. Natl. 
Acad. Sci. USA 86, 3419-3422. 
[15] Wang, J.B., Imai, Y., Eppler, C.M., Gregor, P., Spivak, C., and 
Uhl, G.R. (1993) Proc. Natl. Acad. Sci. USA. 90, 10230-10234. 
[16] Chen, Y., Mestek, A., Liu, J., Hurley, J.A. and Yu, L. (1993) Mol. 
Pharmacol. 44, 8812. 
[17] Fukuda, K., Kato, S., Mori, K., Nishi, M. and Takeshima, H. 
(1993) FEBS Lett. 327, 311-314. 
[18] Evans, C.J., Keith Jr., D.E., Morrison, H., Magendzo, K. and 
Edwards, R.H. (1992) Science 258, 1952-1955. 
[19] Kieffer, B.L., Befort, K., Gaveriaux-Ruff, C. and Hirth, C.G. 
(1992) Proc. Natl. Acad. Sci. USA 89, 12048-12052. 
[20] Yasuda, K., Raynor, K., Kong, H., Breder, C., Takeda, J., 
Reisine, T. and Bell G.I. (1993) Proc. Natl. Acad. Sci. USA 90, 
67366740. 
[21] Minami, M., Toya, T., Katao, Y., Maekawa, K., Nakarnura, S., 
Onogi, T., Kaneko, S. and Satoh, M. (1993) FEBS Lett. 329, 
291-295. 
[22] Nishi, M., Takeshima, H., Fukuda, K., Kato, S. and Mori, K. 
(1993) FEBS Lett. 330, 77-80. 
[23] Johnson, P.S., Wang, J.B., Wang, W.F. and Uhl, G.R. (1994) 
NemoReports 5, 507-509. 
[24] Ward, S.J. and Takemori, A.E. (1983) J. Pharmacol. Exp. Ther. 
224, 5255530. 
[25] Goodman, R.R., Snyder, S.H., Kuhar, M.J. and Young, W.S. 
(1980) Proc. Natl. Acad. Sci. USA 77, 62396243. 
[26] Goodman, R.R. and Pastemak, G.W. (1985) Proc. Natl. Acad. 
Sci. USA 82, 6667-6671. 
[27] Tempel, A. and Zukin, S. (1987) Proc. Natl. Acad. Sci. USA 84, 
430843 12. 
[28] Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H. and Wat- 
son, S.J. (1987) J. Neurosci. 7, 2445-2464. 
[29] Kitayama, S., Shimada, S. and Uhl G.R. (1992) Ann. Neurol. 32, 
109-111. 
[30] Gregor, P., Yang, X., Mano, I., Takemura, M., Teichberg, V. and 
Uhl, G.R. (1992) Mol. Brain Res. 16, 179-186. 
[31] Bhatt, B., Bums, J., Flannery, D. and McGee, J. (1988) Nucleic 
Acids Res. 16, 3951-3961. 
[32] Lichter, P., Tang, C., Call, K., Hermanson, G., Evans, G., 
Housman, D. and Ward, D. (1990) Science 247, 6469. 
[33] Devereux, J., Haeberli, P. and Smithies, 0. (1984) Nucleic Acids 
Res. 12, 387-395. 
[34] Smith, S.S., O’Hara, B.F., Persico, A.M., Gorelick, D.A., Newlin, 
D.B., Vlahov, D., Solomon, L., Pickens, R. and Uhl, G.R. (1992) 
Arch. Gen. Psych. 49, 723-727. 
[35] Persico, A.M., Vandenbergh, D.J., Smith, S.S. and Uhl, G.R. 
(1993) Biol. Psych. 34, 265-267. 
[36] Li, X.J., Forte, M., North, R.A., Ross, CA. and Snyder, S.H. 
(1992) J. Biol. Chem. 267, 21307-21312. 
[37] Buckland, P.R., Hill, R.M., Tidmarsh, S.F. and McGuffin, P. 
(1990) Nucleic Acids Res. 18, 682-682. 
[38] Kazmi, S.M. and Mishra, R.K. (1987) Mol. Pharmacol. 32, 109- 
118. 
[39] Toll, L. (1990) Eur. J. Pharmacol. 176, 213-217. 
222 
[40] Costa, E.M., Hoffman, B.B. and Loew, G.H. (1992) Life Sci. 50, 
73-81. 
[41] Yu, V.C., Hochhaus, G., Chang, F.-H., Richards, M., Bourne, H. 
and Sadee, W. (1988) J. Neurochem. 51, 1892-1899. 
[42] Pastemak, G.W. and Wood, P.J. (1986) Life Sci. 38, 1889-1898. 
[43] Eppler, CM., Hulmes, J.D., Wang, J.B., Johnson, B., Corhbett, 
M., Luthin, D.R., Uhl, G.R. and Linden, J. (1993) J. Biol. Chem. 
268, 26447-26450. 
J.-B. Wang et al. I FEBS Letters 338 (1994) 217-222 
[44] Goldberg, J., Lyons, M.J., Eisen, S.A., True, W.R. and Tsuang, 
M. (1993) Behav. Genet. Sot. Abstr. 
[45] Pickens, R.W., Svikis, D.S., McGue, M., Lykken, D.T., Heston, 
L.L. and Clayton, P.J. (1991) Arch. Gen. Psych. 48, 19-28. 
[46] Uhl, G.R., LaBuda, M., Elmer, G. and Pickens, R. (1994) in 
Meltzer, H. (ed.) Psychopharmacology: A Fourth Generation of 
Progress, in press. 
